SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more
SciVision Biotech Inc (1786) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.008x
Based on the latest financial reports, SciVision Biotech Inc (1786) has a cash flow conversion efficiency ratio of 0.008x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$15.41 Million) by net assets (NT$1.92 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SciVision Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how SciVision Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SciVision Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SciVision Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flügger group A/S
CO:FLUG-B
|
0.002x |
|
Hanjin Transportation Co. Ltd.
KO:002320
|
0.031x |
|
Suzhou Mingzhi Technology Co. Ltd. A
SHG:688355
|
0.130x |
|
POLIGHT ASA NK -04
F:3OL0
|
N/A |
|
InBankshares Corp
OTCQX:INBC
|
N/A |
|
TFF GROUP S.A. INH.EO-40
F:5L1
|
N/A |
|
HAIT.UT.INT.FIN.L. H YC 1
F:HA6
|
N/A |
|
GrafTech International Ltd
NYSE:EAF
|
0.080x |
Annual Cash Flow Conversion Efficiency for SciVision Biotech Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of SciVision Biotech Inc from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.90 Billion | NT$269.87 Million | 0.142x | -14.94% |
| 2023-12-31 | NT$1.63 Billion | NT$272.01 Million | 0.167x | +41.79% |
| 2022-12-31 | NT$1.51 Billion | NT$178.21 Million | 0.118x | +73.60% |
| 2021-12-31 | NT$1.45 Billion | NT$98.51 Million | 0.068x | -24.57% |
| 2020-12-31 | NT$1.40 Billion | NT$126.47 Million | 0.090x | -40.04% |
| 2019-12-31 | NT$1.36 Billion | NT$204.40 Million | 0.150x | +44.98% |
| 2018-12-31 | NT$1.08 Billion | NT$111.70 Million | 0.104x | +492.97% |
| 2017-12-31 | NT$914.45 Million | NT$15.98 Million | 0.017x | -59.19% |
| 2016-12-31 | NT$894.21 Million | NT$38.29 Million | 0.043x | -18.46% |
| 2015-12-31 | NT$948.60 Million | NT$49.81 Million | 0.053x | +2800.57% |
| 2014-12-31 | NT$1.02 Billion | NT$1.85 Million | 0.002x | -94.74% |
| 2013-12-31 | NT$1.08 Billion | NT$37.27 Million | 0.034x | -71.56% |
| 2012-12-31 | NT$425.98 Million | NT$51.52 Million | 0.121x | +18.47% |
| 2011-12-31 | NT$363.70 Million | NT$37.13 Million | 0.102x | +66.58% |
| 2010-12-31 | NT$111.73 Million | NT$6.85 Million | 0.061x | +114.28% |
| 2009-12-31 | NT$84.09 Million | NT$-36.09 Million | -0.429x | -- |